Pfizer (PFE)
(Delayed Data from NYSE)
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Biogen Inks Two Deals to Make Drugs for Neurological Diseases
by Zacks Equity Research
Biogen (BIIB) signs deals with C4 Therapeutics and Skyhawk Therapeutics to develop potential therapies for Alzheimer's disease (AD), Parkinson's disease and other neurological diseases.
Company News For Jan 7, 2019
by Zacks Equity Research
Companies In The News Are: GME,CEO,TSLA,PFE
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie
Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate
by Zacks Equity Research
Bristol-Myers (BMY) is spending $74 billion to buy Celgene. Merck (MRK) exercises option to gain rights to a NASH candidate from partner NGM Biopharmaceuticals.
Nektar, ImaginAb Enter Into Immuno-Oncology Collaboration
by Zacks Equity Research
Nektar (NKTR) and ImaginAb enter into a license and clinical trial collaboration, allowing Nektar to use ImaginAb's immuno-oncology imaging technology.
Pfizer Begins Pivotal Study on Alopecia Areata Candidate
by Zacks Equity Research
Pfizer (PFE) initiates a pivotal phase IIb/III study to evaluate JAK3 inhibitor, PF-06651600, for treating moderate to severe alopecia areata.
Will Pfizer's (PFE) Stock Keep Up the Momentum in 2019?
by Zacks Equity Research
Pfizer (PFE) performs better than the industry in 2018 and looks well poised to keep the positive momentum alive in 2019.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $42.97, moving +0.28% from the previous trading session.
Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan
by Zacks Equity Research
Conatus (CNAT) concentrates on the development of its lead candidate emricasan for treating patients with fibrosis or cirrhosis caused by NASH.
Will AbbVie (ABBV) Shares Regain Lost Momentum in 2019?
by Zacks Equity Research
Though AbbVie's (ABBV) stock was down this year, it looks well poised for a recovery in 2019.
Pfizer/Merck KGaA End Bavencio Ovarian Cancer Phase III Study
by Zacks Equity Research
Pfizer (PFE) and Merck KGaA terminate a late-stage study on Bavencio. This is the second ovarian cancer study failure in less than two months.
AbbVie (ABBV) Seeks Approval for RA Candidate Upadacitinib
by Zacks Equity Research
AbbVie (ABBV) submits regulatory applications in the United States and EU for upadacitinib, for the treatment of adult patients with moderate to severe rheumatoid arthritis.
Pfizer Xtandi Succeeds in Late-Stage Prostate Cancer Study
by Zacks Equity Research
Pfizer's (PFE) prostate cancer drug, Xtandi, met the primary endpoint in a late-stage study that can expand the label of the drug to include hormone-sensitive patients.
Pharma Stock Roundup: GSK, PFE Ink Consumer Health JV, JNJ Hit by Talc Allegations
by Zacks Equity Research
Glaxo (GSK) and Pfizer (PFE) agree to merge their consumer healthcare units into a new JV. J&J stock hit by reports alleging it of being aware of the presence of asbestos in baby powder.
Company News For Dec 20, 2018
by Zacks Equity Research
Companies In The News Are: FDX,GIS,LLY,PFE,GSK
Glaxo, Pfizer to Merge Consumer Health Units, Form New JV
by Zacks Equity Research
Glaxo (GSK) and Pfizer agree to merge their consumer healthcare units into a new joint venture (JV) with almost $13 billion in annual sales. Glaxo will eventually spin-off the joint venture.
Do Options Traders Know Something About Pfizer (PFE) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Pfizer (PFE) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights: Walmart, Pfizer, Adobe, Johnson & Johnson and IBM
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Walmart, Pfizer, Adobe, Johnson & Johnson and IBM
Top Research Reports for Walmart, Pfizer & Adobe
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), Pfizer (PFE) and Adobe (ADBE).
Pfizer (PFE) Stock Moves -1.58%: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $43.11, marking a -1.58% move from the previous day.
Pfizer's (PFE) Biosimilar of Avastin Gets Positive CHMP Nod
by Zacks Equity Research
Pfizer (PFE) gets positive CHMP opinion for Zirabev (bevacizumab), a potential biosimilar to Roche's Avastin (bevacizumab).
Lilly (LLY) to Acquire Pain Candidate From Private Biotech
by Zacks Equity Research
Lilly (LLY) inks a deal with privately held Hydra Biosciences to add the latter's pre-clinical pain candidate to its portfolio.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.